| A role for the two-helix finger of the SecA ATPase in protein translocation KJ Erlandson, SBM Miller, Y Nam, AR Osborne, J Zimmer, TA Rapoport Nature 455 (7215), 984, 2008 | 174 | 2008 |
| The plug domain of the SecY protein stabilizes the closed state of the translocation channel and maintains a membrane seal W Li, S Schulman, D Boyd, K Erlandson, J Beckwith, TA Rapoport Molecular cell 26 (4), 511-521, 2007 | 165 | 2007 |
| Development of clinical-stage human monoclonal antibodies that treat advanced Ebola virus disease in nonhuman primates KE Pascal, D Dudgeon, JC Trefry, M Anantpadma, Y Sakurai, CD Murin, ... The Journal of infectious diseases 218 (suppl_5), S612-S626, 2018 | 157 | 2018 |
| Determining the conductance of the SecY protein translocation channel for small molecules SM Saparov, K Erlandson, K Cannon, J Schaletzky, S Schulman, ... Molecular cell 26 (4), 501-509, 2007 | 142 | 2007 |
| A target site for template-based design of measles virus entry inhibitors RK Plemper, KJ Erlandson, AS Lakdawala, A Sun, A Prussia, ... Proceedings of the National Academy of Sciences 101 (15), 5628-5633, 2004 | 101 | 2004 |
| SARS-CoV-2 BA. 1 variant is neutralized by vaccine booster–elicited serum but evades most convalescent serum and therapeutic antibodies S Lusvarghi, SD Pollett, SN Neerukonda, W Wang, R Wang, R Vassell, ... Science Translational Medicine 14 (645), eabn8543, 2022 | 78 | 2022 |
| Analysis of polypeptide movement in the SecY channel during SecA-mediated protein translocation KJ Erlandson, E Or, AR Osborne, TA Rapoport Journal of Biological Chemistry 283 (23), 15709-15715, 2008 | 50 | 2008 |
| SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster S Lusvarghi, SD Pollett, SN Neerukonda, W Wang, R Wang, R Vassell, ... BioRxiv, 2021 | 41 | 2021 |
| Key substitutions in the spike protein of SARS-CoV-2 variants can predict resistance to monoclonal antibodies, but other substitutions can modify the effects S Lusvarghi, W Wang, R Herrup, SN Neerukonda, R Vassell, L Bentley, ... Journal of virology 96 (1), e01110-21, 2022 | 31 | 2022 |
| Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets E de Wit, F Feldmann, A Okumura, E Horne, E Haddock, G Saturday, ... Antiviral research 156, 64-71, 2018 | 30 | 2018 |
| SARS-COV-2 Delta variant displays moderate resistance to neutralizing antibodies and spike protein properties of higher soluble ACE2 sensitivity, enhanced cleavage and … SN Neerukonda, R Vassell, S Lusvarghi, R Wang, F Echegaray, L Bentley, ... Viruses 13 (12), 2485, 2021 | 26 | 2021 |
| Duplication of the A17L locus of vaccinia virus provides an alternate route to rifampin resistance KJ Erlandson, CA Cotter, JC Charity, C Martens, ER Fischer, SM Ricklefs, ... Journal of Virology 88 (19), 11576-11585, 2014 | 25 | 2014 |
| Human monoclonal antibody 81.39 a effectively neutralizes emerging influenza A viruses of group 1 and 2 hemagglutinins H Marjuki, VP Mishin, N Chai, MW Tan, EM Newton, J Tegeris, ... Journal of virology 90 (23), 10446-10458, 2016 | 17 | 2016 |
| Development of medical countermeasures to Middle East respiratory syndrome coronavirus TM Uyeki, KJ Erlandson, G Korch, M O’Hara, M Wathen, J Hu-Primmer, ... Emerging infectious diseases 22 (7), 2016 | 17 | 2016 |
| Poxviruses encode a reticulon-like protein that promotes membrane curvature KJ Erlandson, H Bisht, AS Weisberg, SI Hyun, BT Hansen, ER Fischer, ... Cell reports 14 (9), 2084-2091, 2016 | 17 | 2016 |
| Molluscum contagiosum virus transcriptome in abortively infected cultured cells and a human skin lesion JD Mendez-Rios, Z Yang, KJ Erlandson, JI Cohen, CA Martens, DP Bruno, ... Journal of virology 90 (9), 4469-4480, 2016 | 13 | 2016 |
| Neutralizing monoclonal antibody use and COVID-19 infection outcomes N Ambrose, A Amin, B Anderson, J Barrera-Oro, M Bertagnolli, F Campion, ... JAMA Network Open 6 (4), e239694-e239694, 2023 | 9 | 2023 |
| SARS-CoV-2 BA. 1 variant is neutralized by vaccine booster-elicited serum, but evades most convalescent serum and therapeutic antibodies. Sci Transl Med 14: eabn8543 S Lusvarghi, SD Pollett, SN Neerukonda, W Wang, R Wang, R Vassell, ... | 6 | 2022 |
| SARS-CoV-2 BA. 1 variant is neutralized by vaccine booster-elicited serum but evades most convalescent serum and therapeutic antibodies. Sci Transl Med. 2022; 14 (645): eabn8543 S Lusvarghi, SD Pollett, SN Neerukonda, W Wang, R Wang, R Vassell, ... | 5 | |
| The influence of social determinants on receiving outpatient treatment with monoclonal antibodies, disease risk, and effectiveness for covid-19 N Ambrose, A Amin, B Anderson, M Bertagnolli, F Campion, D Chow, ... Journal of general internal medicine 38 (16), 3472-3481, 2023 | 3 | 2023 |
Sol SchulmanBeth Israel Deaconess Medical CenterVerified email at bidmc.harvard.edu
